Jamaica's Ministry Of Health
Approves United Cannabis Corporation's Sublingual and Transdermal
Prana Products For Its Registered Medicinal Cannabis
List
Company Now Has 17 Products
Registered and Approved With The Ministry
Denver, CO -- December 14, 2017 -- InvestorsHub NewsWire --
United Cannabis Corporation (OTCQB:
CNAB) (the "Company" or "United Cannabis") today announced that
Jamaica's Ministry of Health has approved its patent-protected
Prana Medicinal Sublinguals and Prana Medicinal Transdermals for
use by registered medicinal cannabis patients.
The Prana Collection is the foundation of the Company's
cannabis-centric formulations, which patients have found effective
in providing relief from the symptoms of arthritis, neuropathy,
acute pain, joint aches, muscle tension, muscle spasms, muscle
recovery, migraines, and various skin conditions.
The products will be manufactured and distributed by the
Company's Jamaican subsidiary, Cannabinoid Research &
Development Limited ("CRD"). CRD is currently making preparations
to produce the complete line of Prana products in Jamaica in
anticipation of receiving a license from the Cannabis Licensing
Authority.
Earnest Blackmon, Chief Executive Officer of United Cannabis,
commented on the announcement, "Jamaica remains at the forefront of
the medical cannabis market, both domestically and as a
distribution hub for other markets around the world, including
Canada, the European Union and Australia. Our partners at CRD are
working to establish relationships with potential distributors in
those markets so that we're ready to initiate sales as soon as we
are licensed to begin production."
About Cannabinoid Research & Development Limited
Cannabinoid Research & Development (CRD), a subsidiary of
United Cannabis, is a Jamaican based corporation pursuing local
licensing to advance the use of medical cannabis therapies through
biomedical research and development for the nutraceutical
industry. CRD focuses on genetic restoration, cannabinoid isolation
techniques, scientific research, educational programs, and promotes
domestic job opportunities. John Sayers, along with Kenyama Brown,
local Jamaican directors and executives of CRD, coupled with
Jamaican partners specializing in agricultural science and plant
based medicine, will help United Cannabis implement Sayer's 40
years of agricultural methodologies into localized educational
curriculums, job training programs, and help with integration of
localized products.
About United Cannabis Corporation
United Cannabis Corporation is a biotechnology company dedicated
to the development of phyto-therapeutic based products supported by
patented technologies for the pharmaceutical, medical, and
industrial markets. The Company has long advocated the application
of cannabinoids for medical applications and is building a platform
for designing targeted therapies to increase the quality of life
for patients around the world. Most of the Company's products are
patent protected first in class medicines with applications to a
global market. United Cannabis trades on the OTCQB under the symbol
CNAB.
For further information, please visit www.unitedcannabis.us.
Contact: Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933, are subject to Rule 3b-6 under the
Securities Exchange Act of 1934, and are subject to the safe
harbors created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and other results and
further events could differ materially from those anticipated in
such statements. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements.